Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?

MED's Valuation Looks Cheap on Forward Sales

MED trades at 0.5X forward 12-month sales, below the food-miscellaneous sub-industry multiple of 0.81X. That discount gives the stock an inexpensive look relative to its peer group and leaves room for re-rating if operating trends improve.

The valuation case is less clear against Medifast’s own history. Its current multiple is above the one-year median of 0.4X, so the stock is not unusually cheap by that measure. A discounted peer multiple alone does not remove the execution risk surrounding the turnaround.

Image Source: Zacks Investment Research

Medifast's Cash Cushion Reduces Balance Sheet Risk

Medifast ended the second quarter of 2026 with $169.8 million in cash, cash equivalents and investments and no debt. Working capital was $160.5 million, compared with $158.7 million at the end of 2025.

That liquidity gives the company flexibility to fund the Trilivy rollout and restructuring while operating results remain under pressure. Second-quarter revenues fell 27.6% year over year to $76.4 million, and Medifast posted a net loss of $3.1 million, or 28 cents per share.

MED's Turnaround Still Depends on Coach Recovery

The coach network remains the biggest operating vulnerability. Active earning coaches fell 48.7% year over year to 11,700 in the second quarter, even as revenue per active earning coach rose 41% to $6,529 and increased sequentially for a third consecutive quarter.

Medifast reported a second-quarter loss of 28 cents per share, substantially narrower than the consensus loss of 67 cents. Revenues also came in slightly above expectations, giving investors a better-than-feared quarterly result even as year-over-year sales remained weak.

Peer comparisons also matter. Mama's Creations, Inc. MAMA and US Foods Holding Corp. USFD provide additional context for MED's positioning within the broader food industry. Medifast still needs productivity gains to translate into stronger client acquisition and renewed coach growth. Medifast's Profitability Goal Raises the Stakes

Management is targeting a return to profitability beginning in the fourth quarter of 2026. The plan rests on revenue stabilization, the Trilivy product rollout and the Catalyst program, which is designed to reduce costs through facility rationalization, artificial-intelligence-related efficiencies and other measures.

The financial outlook shows how much work remains. Medifast expects 2026 revenues of $270 million to $300 million and a loss of 25 cents to $1.75 per share. Management also expects working capital to remain above $145 million at year-end, preserving financial flexibility as the turnaround progresses.

MED's Style Scores Argue for Selectivity

The stock currently carries a Zacks Rank #3 (Hold), which points to a more balanced near-term setup than an outright buy signal. Medifast also has a Momentum Score of A, indicating favorable momentum characteristics, but that strength is not matched across the other styles. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

MED has a Value Score of D, a VGM Score of D and a Growth Score of F. Zacks Style Scores are designed to complement the Zacks Rank, with stronger grades generally preferred. For investors weighing a low sales multiple against turnaround risk, the current mix supports a selective wait-and-see stance until operating improvement becomes more established.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research